[go: up one dir, main page]

UA116499C2 - (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині - Google Patents

(r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині

Info

Publication number
UA116499C2
UA116499C2 UAA201611333A UAA201611333A UA116499C2 UA 116499 C2 UA116499 C2 UA 116499C2 UA A201611333 A UAA201611333 A UA A201611333A UA A201611333 A UAA201611333 A UA A201611333A UA 116499 C2 UA116499 C2 UA 116499C2
Authority
UA
Ukraine
Prior art keywords
pirlindol
medicinal use
pharmaceutically accepted
accepted salts
salts
Prior art date
Application number
UAA201611333A
Other languages
English (en)
Inventor
Філіпі Ауґушту Еуженью Пардал
Педрозу Педру Філіпі Еуфразью
Пекореллі Сузана Маркеш Алмейда
Кайшаду Карлуш Алберту Еуфразью Казіміру
Ана Софья да Консейсан Лопеш
Жуан Карлуш Рамуш Даміл
Original Assignee
Текнімеді Сос'Єдаді Текніку-Медісінал С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Текнімеді Сос'Єдаді Текніку-Медісінал С.А. filed Critical Текнімеді Сос'Єдаді Текніку-Медісінал С.А.
Publication of UA116499C2 publication Critical patent/UA116499C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

(R)-пірліндол або його фармацевтично прийнятні солі, а також фармацевтичні композиції, які містять його, для застосування в терапевтичному лікуванні та запобіганні болю.
UAA201611333A 2014-05-09 2014-05-09 (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині UA116499C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000028 WO2015171004A1 (en) 2014-05-09 2014-05-09 (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine

Publications (1)

Publication Number Publication Date
UA116499C2 true UA116499C2 (uk) 2018-03-26

Family

ID=50819930

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201611333A UA116499C2 (uk) 2014-05-09 2014-05-09 (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині

Country Status (29)

Country Link
US (2) US20170145015A1 (uk)
EP (1) EP3054950B1 (uk)
JP (1) JP2017514884A (uk)
KR (1) KR102232198B1 (uk)
CN (1) CN106413714A (uk)
AU (1) AU2014393489B2 (uk)
CA (1) CA2948596C (uk)
CY (1) CY1119522T1 (uk)
DK (1) DK3054950T3 (uk)
EC (1) ECSP16086232A (uk)
ES (1) ES2649491T3 (uk)
HR (1) HRP20171650T1 (uk)
HU (1) HUE035030T2 (uk)
IL (1) IL248854B (uk)
LT (1) LT3054950T (uk)
MA (1) MA39448B1 (uk)
MX (1) MX368735B (uk)
NO (1) NO3054950T3 (uk)
NZ (1) NZ726131A (uk)
PH (1) PH12016502236A1 (uk)
PL (1) PL3054950T3 (uk)
PT (1) PT3054950T (uk)
RS (1) RS56590B1 (uk)
RU (1) RU2695607C2 (uk)
SI (1) SI3054950T1 (uk)
SM (1) SMT201700520T1 (uk)
TN (1) TN2016000497A1 (uk)
UA (1) UA116499C2 (uk)
WO (1) WO2015171004A1 (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3139926A1 (en) * 2014-05-09 2017-03-15 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
MA39448B1 (fr) 2014-05-09 2019-12-31 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
US12201441B2 (en) * 2018-06-13 2025-01-21 Children's Medical Center Corporation Biomarkers of neuropathic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106681A1 (en) * 2002-10-03 2004-06-03 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
JP2006525226A (ja) * 2002-12-24 2006-11-09 ニューロケム (インターナショナル) リミテッド β−アミロイド関連疾患の治療のための治療用製剤
RU2362551C2 (ru) * 2003-09-15 2009-07-27 Вектура Лимитед Фармацевтические композиции для лечения преждевременной эякуляции при помощи легочной ингаляции
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
EP3139926A1 (en) * 2014-05-09 2017-03-15 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
PL3057589T3 (pl) * 2014-05-09 2018-01-31 Tecnimede Sociedade Tecnico Medicinal S (S)-Pirlindol lub jego farmaceutycznie dopuszczalne sole do zastosowania w medycynie
MA39448B1 (fr) 2014-05-09 2019-12-31 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical

Also Published As

Publication number Publication date
PT3054950T (pt) 2017-11-29
LT3054950T (lt) 2017-11-27
IL248854A0 (en) 2017-01-31
CN106413714A (zh) 2017-02-15
CA2948596A1 (en) 2015-11-12
AU2014393489A1 (en) 2016-11-24
RU2016148182A (ru) 2018-06-13
MA39448B1 (fr) 2019-12-31
DK3054950T3 (en) 2017-11-06
MA39448A1 (fr) 2018-08-31
ES2649491T3 (es) 2018-01-12
PH12016502236A1 (en) 2017-02-06
HRP20171650T1 (hr) 2017-12-15
SI3054950T1 (sl) 2017-12-29
HUE035030T2 (en) 2018-05-02
MX2016014701A (es) 2017-05-23
PL3054950T3 (pl) 2018-02-28
US10533012B2 (en) 2020-01-14
EP3054950B1 (en) 2017-08-02
KR102232198B1 (ko) 2021-03-26
AU2014393489B2 (en) 2020-01-02
TN2016000497A1 (en) 2018-04-04
MX368735B (es) 2019-10-14
RS56590B1 (sr) 2018-02-28
WO2015171004A1 (en) 2015-11-12
NZ726131A (en) 2018-12-21
US20180111944A1 (en) 2018-04-26
KR20170003567A (ko) 2017-01-09
IL248854B (en) 2020-05-31
SMT201700520T1 (it) 2018-01-11
NO3054950T3 (uk) 2017-12-30
JP2017514884A (ja) 2017-06-08
EP3054950A1 (en) 2016-08-17
ECSP16086232A (es) 2017-02-24
RU2016148182A3 (uk) 2018-06-13
US20170145015A1 (en) 2017-05-25
RU2695607C2 (ru) 2019-07-24
CY1119522T1 (el) 2018-03-07
CA2948596C (en) 2021-06-08

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MY187540A (en) Compounds active towards bromodomains
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12016502352A1 (en) Pharmaceutical composition
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
TW201613578A (en) Pharmaceutical combinations
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2017001512A (es) Compuestos activos hacia bromodominios.